Τελευταία ενημέρωση :
28/04/2024
Ερευνητικές ομάδες - Clinical Pharmacy Department, University Hospital Necker-Enfants Malades   Pdf  
Γαλλία
νοσοκομείο
Clinical Pharmacy Department, University Hospital Necker-Enfants Malades
Paris
Βιβλιογραφία   Βιβλιογραφία   (11)  
1
Pharmaceutical Oral Formulation of Methionine as a Pediatric Treatment in Inherited Metabolic Disease.
Querin B, Schweitzer-Chaput A, Cisternino S, Auvity S, Fauqueur A-S, Negbane A, Hadchouel A, Schlatter J, Cotteret C. (salvatore.cisternino@aphp.fr)
Pharmaceutics - 2023 - ,15, 957.
2
Stability and Formulation of Erlotinib in Skin Creams.
Nguyen D, Secrétan P-H, Cotteret , Jacques-Gustave E, Greco C, Bodemer C, Schlatter J, Cisternino S. (philippe-henri.secretan@u-psud.fr)
Molecules - 2022 - ; 27(3): 1070.
3
Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease.
Hinterlang M, Sebti M, Cotteret C, Vidal F, Neven B, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
The Scientific World Journal - 2022 -
4
Formulation and stability study of hydroxychloroquine sulfate oral suspensions.
El Mershati S, Thouvenin A , Secretan P-H, De Lonlay P, Tuchmann-Durand C, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
Pharm Dev Technol - 2021 -
5
Stability of pemetrexed diarginine concentrates for solution in vials and diluted in 0.9% sodium chloride and dextrose 5% polyolefin infusion bags.
Vidal F, Cotteret C, Negbane A, Sebti M, Hinterlang M, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
EJHP - 2021 -
6
Stability of 10-mg/mL and 50-mg/mL ketamine oral solutions.
Ancedy D, Sebti M, Postaire M, Vidal F, Cisternino S. ()
Am J Hosp Pharm - 2021 - ;78,9:825–831
7
Voriconazole topical cream formulation: evidence for stability and antifungal activity.
Bouchand C, Nguyen D, Secretan P-H, Vidal F, Guery R, Auvity S, Cohen J.F, Lanternier (joel.schlatter@aphp.fr)
Int J Antimicrob Agents - 2020 - ; 56: 106083.
8
Stability of warfarin sodium flavoured preservative-free oral liquid formulations.
Schlatter J, Cisternino S. (joel.schlatter@ aphp.fr)
EJHP - 2018 - ; 25, e2
9
Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions.
Amin A, Bourget P, Vidal F, Cartier F, Beauvais R, Do Nascimento Afonso V. ()
Int J Pharm Compound - 2015 - ; 19, 1: 73-77.
10
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition.
Bourget P, Amin A, Vidal F, Pieyre M, Dosso E.O, Beauvais R, Loeuillet R. ()
Int J Pharm Compound - 2014 - ; 18, 5: 427-431.
11
How To Minimize Toxic Exposure to Pyridine during Continuous Infusion of Ceftazidime in Patients with Cystic Fibrosis?
Bourget P, Amin A, Dupont C, Abely M, Desmazes-Dufeu N, Dubus J.C, Jouani B.-L., Merlette C, Nov?-Josserand R, Pages J, Panzo R (philippe.bourget@nck.aphp.fr)
Antimicrob Agents Chemother - 2014 - ; 58 : 2849-2855.

Καταστάσεις   μόρια που μελετήθηκαν   (11)  
Ανοσοκατασταλτικό Πόσιμο διάλυμα Azathioprine
Αντιβιοτικό Ενέσιμο Ceftazidime
φάρμακο κατά του καρκίνου Αλοιφές Erlotinib
Αντιφλεγμονώδες Πόσιμο διάλυμα Hydrocortisone
Αντιφλεγμονώδες Πόσιμο διάλυμα Hydroxychloroquine sulfate
Γενικό αναισθητικό Πόσιμο διάλυμα Ketamine hydrochloride
Λοιπά Πόσιμο διάλυμα L-Methionine
φάρμακο κατά του καρκίνου Ενέσιμο Pemetrexed diarginine
φάρμακο κατά του καρκίνου Πόσιμο διάλυμα Ruxolitinib
Αντιμυκητικό Αλοιφές Voriconazole
Αντιπηκτικό Πόσιμο διάλυμα Warfarin sodium

  Mentions Légales